29 August 2017Asia

AstraZeneca and Takeda enter agreement to develop Parkinson’s disease drug

AstraZeneca and Takeda have entered into an agreement to develop and commercialise MEDI1341, an alpha-synuclein antibody currently in development as a potential treatment for Parkinson’s disease (PD).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Generics

Class-action accuses Takeda of ‘pay-for-delay’ deal with Par

1 July 2021 Takeda Pharmaceuticals organised a pay-for-delay deal with Par Pharmaceuticals to prevent a generic version of its constipation treatment from releasing, according to a complaint submitted to the US District Court for the District of Massachusetts.

Generics

Takeda faces ‘pay-for-delay’ class-action suit over anti-constipation drug

5 August 2021 Takeda Pharmaceuticals is the target of a proposed class action that alleges the pharma giant paid to keep a generic anti-constipation drug off the market.

Generics

Second Circuit says Takeda can’t dodge two antitrust suits

26 August 2021 The US Court of Appeals for the Second Circuit has denied an appeal from Takeda Pharmaceuticals to shut down two antitrust suits related to its diabetes drug Actos.

More on this story

Generics

Class-action accuses Takeda of ‘pay-for-delay’ deal with Par

Generics

Takeda faces ‘pay-for-delay’ class-action suit over anti-constipation drug

5 August 2021 Takeda Pharmaceuticals is the target of a proposed class action that alleges the pharma giant paid to keep a generic anti-constipation drug off the market.

Generics

Second Circuit says Takeda can’t dodge two antitrust suits

26 August 2021 The US Court of Appeals for the Second Circuit has denied an appeal from Takeda Pharmaceuticals to shut down two antitrust suits related to its diabetes drug Actos.

More on this story

Generics

Class-action accuses Takeda of ‘pay-for-delay’ deal with Par

Generics

Takeda faces ‘pay-for-delay’ class-action suit over anti-constipation drug

5 August 2021 Takeda Pharmaceuticals is the target of a proposed class action that alleges the pharma giant paid to keep a generic anti-constipation drug off the market.

Generics

Second Circuit says Takeda can’t dodge two antitrust suits

26 August 2021 The US Court of Appeals for the Second Circuit has denied an appeal from Takeda Pharmaceuticals to shut down two antitrust suits related to its diabetes drug Actos.

More features

Fed Circ orders Teva to delist five patents from Orange Book

Sarepta wins $115M in patent dispute over muscular dystrophy drug

Novartis shields eye-drop patent at European Patent Office

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York

UPC deals further blow to Dexcom in glucose monitor dispute with Abbott

AstraZeneca and Takeda enter agreement to develop Parkinson’s disease drug

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features